Andrés Francesch Solloso

This inventor holds 11 USPTO granted patents and 5 published patent applications, plus 4 CIPO patents and 13 EPO patents. Top assignees: Pharma Mar, S.a., Parma Mar, S.a.. Active years: 2012-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Andrés Francesch Solloso. Retrieved from https://idiyas.com/inventor/andres-francesch-solloso

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 11 (Patent Applications = 5)

% Patents Active = 81.8

CIPO Patents = 4

EPO Patents = 13 (Patent Applications = 17)

Average Co-Inventor Count = 4.1

ph-index = 4

Forward Citations = 36(Granted Patents)

Company Filing History:

Years Active: 2012-2025

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12410148 - Antibody drug conjugates (2025-09-09),

2. 12384800 - Antitumoral compounds (2025-08-12),

3. 11713325 - Antitumoral compounds (2023-08-01),

4. 11339180 - Antitumoral compounds (2022-05-24),

5. 11332480 - Antitumoral compounds (2022-05-17),

6. 11224663 - Antibody drug conjugates (2022-01-18),

7. 10538535 - Antitumoral compounds (2020-01-21),

8. 9428524 - Synthetic process for the manufacture of ecteinascidin compounds (2016-08-30),

9. 8962602 - Anticancer steroidal lactones unsaturated in position 7 (8) (2015-02-24),

10. 8501968 - Antitumoral dihydropyran-2-one compounds (2013-08-06),

11. 8324406 - Antitumoral dihydropyran-2-one compounds (2012-12-04),

Title: The Innovative Contributions of Andres Francesch Solloso

Introduction

Andres Francesch Solloso is a notable inventor based in Madrid, Spain. He has made significant contributions to the field of pharmaceuticals, particularly in the development of antibody drug conjugates and antitumoral compounds. With a total of 11 patents to his name, Solloso's work is paving the way for advancements in cancer treatment.

Latest Patents

His latest patents include innovative formulations such as antibody drug conjugates, which are designed to enhance the efficacy of cancer therapies. One of his notable inventions is a drug conjugate of the formula [D-(X)-(AA)-(L)-]-Ab, which aims to improve targeted drug delivery. Additionally, he has developed antitumoral compounds characterized by a general formula I, along with pharmaceutical compositions, kits, and methods for treating cancer.

Career Highlights

Throughout his career, Solloso has worked with prominent companies in the pharmaceutical industry, including Pharma Mar, S.A. His experience in these organizations has allowed him to contribute to groundbreaking research and development efforts in cancer therapeutics.

Collaborations

Solloso has collaborated with esteemed colleagues such as Maria Del Carmen Cuevas Marchante and Valentin Martinez Barrasa. These partnerships have fostered a collaborative environment that enhances innovation and drives progress in their shared field.

Conclusion

Andres Francesch Solloso's contributions to the pharmaceutical industry exemplify the impact of innovative thinking in the fight against cancer. His patents and collaborations reflect a commitment to advancing medical science and improving patient outcomes.

Profile summary based on public USPTO records.